Dirk J.
- Country
- Germany
- Department
- Nationales Centrum für Tumorerkrankungen (NCT)
Research Overview
- Phase I Study of IMA401 TCER® in Patients with Solid Tumors: Monotherapy and Combination with Checkpoint Inhibitor
- Phase II Randomized Controlled Trial of Autogene Cevumeran Versus Watchful Waiting in ctDNA Positive Resected Stage II/III Colorectal Cancer Patients
- Evaluation of Nivolumab Monotherapy and Nivolumab-Ipilimumab Combination in Advanced or Metastatic Solid Tumors: A Phase 1/2 Open-label Study
Data & Insights
Has run more than one trial at 13 of 68 partner sites.
Specializations
Advanced Cancer Research
Focused on investigating novel treatments for advanced and metastatic solid tumors, with particular emphasis on multiple cancer types including triple-negative breast cancer, gastric cancer, and pancreatic adenocarcinoma.
- Small Cell Lung Cancer
- Bladder Cancer
- Ovarian Cancer
Explores therapeutic approaches utilizing immune checkpoint inhibitors in various tumor contexts.
Immunotherapy Innovation
Specializes in advanced cellular immunotherapy approaches, including the development and implementation of genetically modified T-cell therapies. Investigates novel treatment combinations with immune checkpoint inhibitors.
- ACTengine® Technology
- Bispecific T-cell Receptors
- Combination Immunotherapy Strategies
Focuses on personalized cellular therapeutic approaches for solid tumors.
Colorectal Cancer Treatment
Specializes in the treatment of high-risk colorectal cancer, with particular focus on innovative therapeutic approaches for Stage II and Stage III disease.
- ctDNA-based Patient Selection
- Post-surgical Treatment Strategies
- Disease-Free Survival Optimization
Evaluates novel therapeutic interventions against conventional watchful waiting approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.